1. Home
  2. REGN
  3. REGN News

Latest Regeneron Pharmaceuticals Inc. (REGN) News on November 1, 2025

REGN

MT Newswires

a day ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $4,252,745, According to a Recent SEC Filing

Is OPKO’s Regeneron Deal and Asset Sale Shifting the Investment Case for OPKO Health (OPK)?
REGN

Simply Wall St.

a day ago

Is OPKO’s Regeneron Deal and Asset Sale Shifting the Investment Case for OPKO Health (OPK)?

REGN

MT Newswires

a day ago

Rothschild & Co Redburn Adjusts Price Target on Regeneron Pharmaceuticals to $910 From $900

AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win
REGN

Clinical Trials Arena

a day ago

AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
REGN

GlobeNewswire

a day ago

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential
REGN

PR Newswire

2 days ago

JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential

Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals
REGN

Insider Monkey

2 days ago

Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals

REGN

Morningstar Research

2 days ago

Analyst Report: Intellia Therapeutics, Inc.

Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season
REGN

Simply Wall St.

2 days ago

Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season

What Catalysts Are Driving the Changing Narrative for Regeneron?
REGN

Simply Wall St.

2 days ago

What Catalysts Are Driving the Changing Narrative for Regeneron?

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
REGN

GlobeNewswire

3 days ago

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

REGN

Morningstar Research

3 days ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher?
REGN

Barrons.com

3 days ago

Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher?

REGN

MT Newswires

3 days ago

OPKO's ModeX, Regeneron Collaborate to Develop Antibodies for Therapeutic Indications

FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes
REGN

Pharmaceutical Technology

3 days ago

FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes

REGN

MT Newswires

3 days ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $708 From $704, Keeps Sector Perform Rating

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
REGN

GlobeNewswire

3 days ago

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

REGN

MT Newswires

3 days ago

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $725 From $640, Maintains Outperform Rating

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts
REGN

Investor's Business Daily

4 days ago

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts

Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed?
REGN

Simply Wall St.

4 days ago

Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed?

REGN

MT Newswires

4 days ago

US Equity Indexes Break Records as Fed Set to Cut While Gains Accrue From Earnings, Corporate Actions

Regeneron (REGN) Q3 2025 Earnings Call Transcript
REGN

Motley Fool

4 days ago

Regeneron (REGN) Q3 2025 Earnings Call Transcript

REGN

MT Newswires

4 days ago

US Equity Markets End Higher Amid Expectations of Another Fed Rate Cut

REGN

MT Newswires

4 days ago

Sector Update: Health Care Stocks Fall Late Afternoon

REGN

MT Newswires

4 days ago

JPMorgan Raises Price Target on Regeneron Pharmaceuticals to $850 From $800

REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
REGN

Zacks

4 days ago

REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
REGN

GlobeNewswire

5 days ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
REGN

Business Wire

5 days ago

OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo
REGN

Simply Wall St.

6 days ago

A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo

Regeneron Earnings: What To Look For From REGN
REGN

StockStory

6 days ago

Regeneron Earnings: What To Look For From REGN

European Medicines Agency Adopts a Positive Opinion on ​Regeneron’s (REGN) Libtayo
REGN

Insider Monkey

6 days ago

European Medicines Agency Adopts a Positive Opinion on ​Regeneron’s (REGN) Libtayo

REGN

Morningstar Research

8 days ago

Analyst Report: Sanofi

Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue
REGN

Investor's Business Daily

8 days ago

Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue

Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week
REGN

The Wall Street Journal

8 days ago

Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week

Long Leaf Partners Fund’s Comment on Regeneron (REGN)
REGN

Insider Monkey

8 days ago

Long Leaf Partners Fund’s Comment on Regeneron (REGN)

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
REGN

Zacks

8 days ago

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS
REGN

Zacks

9 days ago

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS

Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline
REGN

Zacks

11 days ago

Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.
REGN

Investor's Business Daily

15 days ago

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.

Is FDA and EMA Progress for Libtayo Transforming the Investment Story for Regeneron (REGN)?
REGN

Simply Wall St.

15 days ago

Is FDA and EMA Progress for Libtayo Transforming the Investment Story for Regeneron (REGN)?

REGN

MT Newswires

15 days ago

Regeneron Says its Libtayo Adjuvant Treatment for Cutaneous Squamous Cell Carcinoma Recommended for EU Approval

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
REGN

GlobeNewswire

15 days ago

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
REGN

Zacks

17 days ago

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)

REGN

MT Newswires

17 days ago

Rothschild & Co Redburn Adjusts Regeneron Pharmaceuticals Price Target to $900 From $890, Maintains Buy Rating

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
REGN

GlobeNewswire

17 days ago

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

Regeneron’s Q3 2025 Earnings: What to Expect
REGN

Barchart

18 days ago

Regeneron’s Q3 2025 Earnings: What to Expect

2 Stocks Down 17% and 21% to Buy Right Now
REGN

Motley Fool

18 days ago

2 Stocks Down 17% and 21% to Buy Right Now

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
REGN

Zacks

19 days ago

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge
REGN

Insider Monkey

19 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge

Stock Market Today: Dow Jumps 400 Points On Trump Tariff Comments; Broadcom, Nvidia, Tesla Rally (Live Coverage)
REGN

Investor's Business Daily

19 days ago

Stock Market Today: Dow Jumps 400 Points On Trump Tariff Comments; Broadcom, Nvidia, Tesla Rally (Live Coverage)

REGN

MT Newswires

20 days ago

Regeneron Says Investigational Hearing Loss Therapy Shows Improvement in Almost All Study Participants

How Should Investors Value Regeneron After the 44% Stock Drop and DCF Surprise?
REGN

Simply Wall St.

20 days ago

How Should Investors Value Regeneron After the 44% Stock Drop and DCF Surprise?

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
REGN

GlobeNewswire

20 days ago

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy
REGN

BioPharma Dive

21 days ago

Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
REGN

Investor's Business Daily

23 days ago

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
REGN

Zacks

23 days ago

Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo

Regeneron, needing a turnaround, gains new use for cancer drug
REGN

BioPharma Dive

23 days ago

Regeneron, needing a turnaround, gains new use for cancer drug

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab
REGN

GlobeNewswire

24 days ago

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

REGN

MT Newswires

24 days ago

Regeneron Says FDA Approved Libtayo as Immunotherapy for Adjuvant Treatment of High Risk Skin Cancer

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
REGN

GlobeNewswire

24 days ago

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

REGN

MT Newswires

24 days ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $704 From $695, Keeps Sector Perform Rating

Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics
REGN

GlobeNewswire

25 days ago

Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics

11 Cheap Stocks for a Market That’s Too Expensive
REGN

Barrons.com

25 days ago

11 Cheap Stocks for a Market That’s Too Expensive

Regeneron (REGN): Reevaluating Valuation Following Breakthrough Trial Results and Evkeeza’s FDA Pediatric Approval
REGN

Simply Wall St.

25 days ago

Regeneron (REGN): Reevaluating Valuation Following Breakthrough Trial Results and Evkeeza’s FDA Pediatric Approval

Health Care Roundup: Market Talk
REGN

The Wall Street Journal

a month ago

Health Care Roundup: Market Talk

REGN

MT Newswires

a month ago

Sector Update: Health Care Stocks Retreat Late Afternoon

REGN

MT Newswires

a month ago

Sector Update: Health Care

REGN

MT Newswires

a month ago

Regeneron Shares Drop After $83 Million Charge Projected to Reduce Q3 EPS

Bullous Pemphigoid Market Analysis and Forecast Report 2025-2035
REGN

GlobeNewswire

a month ago

Bullous Pemphigoid Market Analysis and Forecast Report 2025-2035

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
REGN

Zacks

a month ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management
REGN

Insider Monkey

a month ago

Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management

REGN

Argus Research

a month ago

Analyst Report: Regeneron Phars, Inc

REGN

Argus Research

a month ago

Market Update: PAYX, REGN

Does FDA Approval Expansion and Pipeline Progress Change the Bull Case for Regeneron (REGN)?
REGN

Simply Wall St.

a month ago

Does FDA Approval Expansion and Pipeline Progress Change the Bull Case for Regeneron (REGN)?

LEXX: Biodistribution Study Results
REGN

Zacks Small Cap Research

a month ago

LEXX: Biodistribution Study Results

Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline
REGN

Insider Monkey

a month ago

Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline

Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough
REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough

Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials
REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials

REGN

MT Newswires

a month ago

US Equity Indexes Rise as Healthcare Jumps, October Rate-Cut Certainty Increases Amid Surprise Fall in Private Payrolls

REGN

MT Newswires

a month ago

Healthcare Helps Lift US Equity Indexes After Federal Shutdown Begins

REGN

MT Newswires

a month ago

US Equity Indexes Mixed Amid Healthcare Gains While Treasury Yields Drop as Partial Shutdown Begins

Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals
REGN

GlobeNewswire

a month ago

Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals

Regeneron’s Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5
REGN

Insider Monkey

a month ago

Regeneron’s Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
REGN

GlobeNewswire

a month ago

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025

2 Beaten-Down Stocks to Buy and Hold for a Decade
REGN

Motley Fool

a month ago

2 Beaten-Down Stocks to Buy and Hold for a Decade

Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease
REGN

Insider Monkey

a month ago

Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease

Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2
REGN

Insider Monkey

a month ago

Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2

FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
REGN

Zacks

a month ago

FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza

Regeneron’s Evkeeza gains FDA approval for young HoFH patients
REGN

Pharmaceutical Technology

a month ago

Regeneron’s Evkeeza gains FDA approval for young HoFH patients

1 Healthcare Stock with Exciting Potential and 2 We Ignore
REGN

StockStory

a month ago

1 Healthcare Stock with Exciting Potential and 2 We Ignore

REGN

MT Newswires

a month ago

Regeneron Says Evkeeza Gets FDA Approval for Children as Young as 1-Year Old With Rare Form of High Cholesterol

Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
REGN

GlobeNewswire

a month ago

Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Why Regeneron (REGN) Shares Are Falling Today
REGN

StockStory

a month ago

Why Regeneron (REGN) Shares Are Falling Today

1 Safe-and-Steady Stock on Our Watchlist and 2 We Question
REGN

StockStory

a month ago

1 Safe-and-Steady Stock on Our Watchlist and 2 We Question

Regeneron’s Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide
REGN

Insider Monkey

a month ago

Regeneron’s Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide

Why Regeneron (REGN) Stock Is Down Today
REGN

StockStory

a month ago

Why Regeneron (REGN) Stock Is Down Today

Stock Market Today: Dow Up Ahead Of Powell Speech; Nvidia At Buy Point (Live Coverage)
REGN

Investor's Business Daily

a month ago

Stock Market Today: Dow Up Ahead Of Powell Speech; Nvidia At Buy Point (Live Coverage)

US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall
REGN

Reuters

a month ago

US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall

SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
REGN

Zacks

a month ago

SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU

Humana initiated, Paycom upgraded: Wall Street's top analyst calls
REGN

The Fly

a month ago

Humana initiated, Paycom upgraded: Wall Street's top analyst calls

Share on Social Networks: